These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23078808)

  • 1. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission.
    Jurgens MS; Welsing PM; Jacobs JW
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S56-63. PubMed ID: 23078808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
    Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG
    Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
    Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
    Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treat-to-target: not as simple as it appears.
    Pincus T; Castrejón I; Bergman MJ; Yazici Y
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S10-20. PubMed ID: 23072741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.
    Pincus T; Castrejón I
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S33-40. PubMed ID: 24219039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis.
    Yu C; Jin S; Wang Y; Jiang N; Wu C; Wang Q; Tian X; Li M; Zeng X
    Clin Rheumatol; 2019 Mar; 38(3):727-738. PubMed ID: 30341703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.
    Fautrel B
    Joint Bone Spine; 2018 Dec; 85(6):679-685. PubMed ID: 29452300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
    Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Treat to target' for rheumatoid arthritis in 2014--time tested triple therapy or logical biologics?
    Mok MY; Danda D
    Int J Rheum Dis; 2014 Jan; 17(1):1-3. PubMed ID: 24472259
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcome of patients with rheumatoid arthritis: cross-sectional study of a single-center real-world inception cohort.
    Ling E; Ofer-Shiber S; Goren O; Molad Y
    Isr Med Assoc J; 2013 Dec; 15(12):758-62. PubMed ID: 24449980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies are more important than drugs in the management of rheumatoid arthritis.
    Drosos AA; Pelechas E; Voulgari PV
    Clin Rheumatol; 2020 Apr; 39(4):1363-1368. PubMed ID: 32088801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Puolakka K; Blåfield H; Ilva K; Hannonen P; Leirisalo-Repo M; Möttönen T;
    Ann Rheum Dis; 2014 Apr; 73(4):788-90. PubMed ID: 24297374
    [No Abstract]   [Full Text] [Related]  

  • 19. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the best treatment strategy for early RA?
    Leirisalo-Repo M
    Best Pract Res Clin Rheumatol; 2013 Aug; 27(4):523-36. PubMed ID: 24315052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.